Matthew Harrison analyst SUSQUEHANNA

Currently out of the existing stock ratings of Matthew Harrison, 396 are a HOLD (36.16%), 617 are a BUY (56.35%), 82 are a SELL (7.49%).

Matthew Harrison

Work Performance Price Targets & Ratings Chart

Analyst Matthew Harrison, currently employed at SUSQUEHANNA, carries an average stock price target met ratio of 62.72% that have a potential upside of 31.38% achieved within 316 days. Previously, Matthew Harrison worked at MORGAN STANLEY.

Matthew Harrison’s has documented 2,143 price targets and ratings displayed on 103 stocks. The coverage is on Healthcare, Technology, Basic Materials, Energy, Industrials, Consumer Cyclical, Communication Services sectors.

Most recent stock forecast was given on R, Ryder System.

Wall Street Analyst Matthew Harrison

Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) at 2/23/2016. The price target of $5 was fulfilled within 1 day with a profit of $0.54 (12.11%) receiving and performance score of 121.08.

Average potential price target upside

ADCT ADC Therapeutics SA ADGI Adagio Therapeutics ALVR Allovir ALXN Alexion Pharmaceuticals AMGN Amgen ARGX argenx NV ADR AVIR Atea Pharmaceuticals BGNE BeiGene Ltd BHVN Biohaven Pharmaceutical Holding Co Ltd BIIB Biogen BLUE Bluebird bio BMRN Biomarin Pharmaceutical BMY Bristol-Myers Squibb Company BNTX BioNTech SE CCMP CMC Materials CELG Celgene DNLI Denali Therapeutics EVLO Evelo Biosciences FULC Fulcrum Therapeutics FUSN Fusion Pharmaceuticals GBT Global Blood Therapeutics GLPG Galapagos NV ADR HUN Huntsman IMGN ImmunoGen INSM Insmed KLDO Kaleido Biosciences KOD Kodiak Sciences LEGN Legend Biotech Corp MRK Merck mpany MRNA Moderna PFE Pfizer PTLA Portola Pharmaceuticals REGN Regeneron Pharmaceuticals RPM RPM International SGEN Seagen SGTX Sigilon Therapeutics SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals VVV Valvoline ABBV AbbVie GILD Gilead Sciences JNJ Johnson & Johnson RDUS Schnitzer Steel Industries SAGE Sage Therapeutic ALNY Alnylam Pharmaceuticals CERE Cerevel Therapeutics Holdings CNTA Centessa Pharmaceuticals PLC ADR EDIT Editas Medicine FUL H B Fuller Company GMAB Genmab AS IMMU Immunomedics IMRA Imara LLY Eli Lilly and Company RGNX Regenxbio TSVT 2Seventy Bio ADAG Adagene AKRO Akero Therapeutics BOLT Bolt Biotherapeutics PHVS Pharvaris BV VACC XLRN Acceleron Pharma ALEC Alector CABA Cabaletta Bio CYTK Cytokinetics INCY yte RUBY Rubius Therapeutics ZNTL Zentalis Pharmaceuticals Llc SANA Sana Biotechnology TNYA Tenaya Therapeutics APD Air Products and Chemicals AXTA Axalta Coating Systems Ltd CMRX Chimerix ENTG Entegris FTSV Forty Seven GRA W. R. Grace INVA Innoviva IOBT IO Biotech IVVD Invivyd KOP Koppers Holdings KWR Quaker Chemical LYEL Lyell Immunopharma MTX Minerals Technologies SHW Sherwin-Williams Co UBX Unity Biotechnology VIGL Vigil Neuroscience DBVT DBV Technologies LIN Linde plc Ordinary Shares FMC FMC AVNT Avient Corp TSHA Taysha Gene Therapies PRME Prime Medicine, Common Stock COGT Cogent Biosciences R Ryder System AL Air Lease ALV Autoliv BL Blackline CE Celanese SA Seabridge Gold SG Sweetgreen TS Tenaris SA ADR VYGR Voyager Therapeutics CMCSA Comcast Corp LYV Live Nation Entertainment

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 28-Mar-2024

$5

$3.87 (342.48%)

$10

1 months 16 days ago
(17-Aug-2026)

0/5 (0%)

$3.9 (354.55%)

Buy Since 29-Oct-2020

$8

3 months 25 days ago
(08-Jun-2026)

0/16 (0%)

$4.24 (112.77%)

Buy Since 05-May-2026

$2

$0.87 (76.99%)

$6

3 months 29 days ago
(04-Jun-2026)

0/3 (0%)

$0.68 (51.52%)

Buy Since 10-May-2022

$5

$3.98 (390.20%)

$8

1 years 3 months 13 days ago
(20-Jun-2025)

0/13 (0%)

$2.23 (80.51%)

Buy Since 08-Nov-2024

$8

$6.98 (684.31%)

$6

1 years 7 months 9 days ago
(24-Feb-2025)

0/2 (0%)

$6.4 (400.00%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Matthew Harrison most bullish on?

Potential upside of $260.79 has been obtained for ARGX (ARGENX NV ADR)

Which stock is Matthew Harrison most reserved on?

Potential downside of -$151.01 has been obtained for MRNA (MODERNA)

What Year was the first public recommendation made by Matthew Harrison?

On 2012
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?